MetLife Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-55,182
| Closed | -$86.6K | – | 2837 |
|
|
2024
Q3 | $86.6K | Hold |
55,182
| – | – | ﹤0.01% | 2680 |
|
|
2024
Q2 | $92.7K | Buy |
55,182
+22,320
| +68% | +$37.5K | ﹤0.01% | 2642 |
|
|
2024
Q1 | $78.9K | Buy |
+32,862
| New | +$78.9K | ﹤0.01% | 2639 |
|
|
2023
Q4 | – | Sell |
-42,834
| Closed | -$46.7K | – | 2850 |
|
|
2023
Q3 | $46.7K | Hold |
42,834
| – | – | ﹤0.01% | 2837 |
|
|
2023
Q2 | $98.1K | Hold |
42,834
| – | – | ﹤0.01% | 2691 |
|
|
2023
Q1 | $104K | Buy |
42,834
+20,999
| +96% | +$51K | ﹤0.01% | 2534 |
|
|
2022
Q4 | $41.7K | Sell |
21,835
-18,221
| -45% | -$34.8K | ﹤0.01% | 2774 |
|
|
2022
Q3 | $96.1K | Buy |
+40,056
| New | +$96.1K | ﹤0.01% | 2691 |
|
|
2022
Q1 | – | Sell |
-25,604
| Closed | -$101K | – | 2755 |
|
|
2021
Q4 | $101K | Hold |
25,604
| – | – | ﹤0.01% | 2404 |
|
|
2021
Q3 | $123K | Buy |
+25,604
| New | +$123K | ﹤0.01% | 2347 |
|
|
2019
Q3 | – | Sell |
-23,843
| Closed | -$150K | – | 2365 |
|
|
2019
Q2 | $150K | Hold |
23,843
| – | – | ﹤0.01% | 2190 |
|
|
2019
Q1 | $133K | Hold |
23,843
| – | – | ﹤0.01% | 2199 |
|
|
2018
Q4 | $158K | Hold |
23,843
| – | – | ﹤0.01% | 2039 |
|
|
2018
Q3 | $254K | Hold |
23,843
| – | – | ﹤0.01% | 1950 |
|
|
2018
Q2 | $286K | Hold |
23,843
| – | – | ﹤0.01% | 1738 |
|
|
2018
Q1 | $204K | Hold |
23,843
| – | – | ﹤0.01% | 1882 |
|
|
2017
Q4 | $236K | Buy |
+23,843
| New | +$236K | ﹤0.01% | 1838 |
|